Amarin Corp Plc (AMRN)

[lettruthringout]

Reddy CEO thinks entitled to entire Vascepa market

January 28th, 2022
Moderator: The next question is from the line of Sameer Baisiwala from Morgan Stanley. Please go ahead.

Sameer Baisiwala: Sir, the first question is on icosapent which is Vascepa in the US. Good job done on the market share gain. I think it's now stabilizing around 11-12% for the last few weeks. Have we reached the peak or what's the outlook over here? And is it the supply that is holding you back?

Erez Israeli: I think that the product is doing well. We are planning to continue to do well also in the next quarters to come. There is still a lot of market share to gain with this product as the innovator is still holding a nice market share. And in terms of supply, it is not constraining us at this stage.

Sameer Baisiwala: Then why is the market share in early double-digit and not much higher if supply is not holding you back? What's the roadblock?


Erez Israeli: The roadblock is the desire of customers to take the product from us.

Sameer Baisiwala: But that's a little counterintuitive because generic is lower priced. So, most of the time, customers are too happy to take generic products. Is anything different over here?

Erez Israeli: No, nothing different here.